Chinese bats likely source of SARS virus

An international research team -- with participants in China, Australia, Singapore and the U.S. -- has published its results in the journal Nature. "Our discovery that bats carrying SARS-CoV may be able to directly infect humans has enormous implications for public health control measures," stated co-author Dr. Peter Daszak, president of the New York-based EcoHealth Alliance. Daszak is principal investigator on an NIH/National Science Foundation (NSF) Ecology and Evolution of Infectious Diseases (EEID) grant that provided some project funding.

The results are based on genetic analysis of samples taken over the course of a year from members of a horseshoe bat colony in Kunming, China. At least seven different strains of SL-CoVs were found to be circulating within the single group of bats. The findings highlight the importance of research programs targeting high-risk wildlife groups in emerging disease hotspots to predict, prepare for, and prevent pandemics, the researchers suggest.

"Our findings suggest that SARS-like coronaviruses are diverse and abundant in bats in Asia, and the potential for future spillover remains high," Daszak noted. "If we add this to the recent finding that Middle East respiratory syndrome coronavirus (MERS-CoV) originates in Saudi Arabian bats, it's strong evidence that bat coronaviruses remain a substantial global threat to public health."

The EEID program is a joint NIH-NSF initiative that supports efforts to understand the underlying ecological and biological mechanisms that govern relationships between human-induced environmental changes and the emergence and transmission of infectious diseases. The highly interdisciplinary research projects supported apply both ecological and biomedical methods, and study how environmental events such as habitat alteration, biological invasion, climate change, and pollution alter the risks of emergence and transmission of viral, parasitic, and bacterial diseases in humans and other animals. Fogarty manages NIH participation in the venture and oversees the Daszak award (R01TW005869).

Additional U.S. government funding for the research came from the National Institute of Allergy and Infectious Diseases at NIH (R01AI079231), a Fogarty award supported with International Influenza Funds from the Department of Health and Human Services (R56TW009502) and the United States Agency for International Development (USAID) Emerging Pandemic Threats PREDICT initiative. The State Key Program for Basic Research and the National Natural Science Foundation of China also provided support.